Last reviewed · How we verify
Muscle Relaxant (Rocuronium)
Rocuronium blocks acetylcholine receptors at the neuromuscular junction, preventing muscle contraction and causing paralysis.
Rocuronium blocks acetylcholine receptors at the neuromuscular junction, preventing muscle contraction and causing paralysis. Used for Facilitation of endotracheal intubation during anesthesia induction, Maintenance of neuromuscular blockade during general anesthesia for surgical procedures.
At a glance
| Generic name | Muscle Relaxant (Rocuronium) |
|---|---|
| Also known as | Esmeron MSD |
| Sponsor | Ostfold Hospital Trust |
| Drug class | Non-depolarizing neuromuscular blocking agent |
| Target | Nicotinic acetylcholine receptor (neuromuscular junction) |
| Modality | Small molecule |
| Therapeutic area | Anesthesiology |
| Phase | FDA-approved |
Mechanism of action
Rocuronium is a non-depolarizing neuromuscular blocking agent that competitively antagonizes acetylcholine at the nicotinic receptors on the motor end plate. By occupying these receptors, it prevents acetylcholine from binding and initiating muscle contraction, resulting in skeletal muscle paralysis. This effect is reversible and used during anesthesia to facilitate intubation and surgical procedures.
Approved indications
- Facilitation of endotracheal intubation during anesthesia induction
- Maintenance of neuromuscular blockade during general anesthesia for surgical procedures
Common side effects
- Prolonged neuromuscular blockade
- Histamine release (flushing, hypotension, tachycardia)
- Anaphylaxis
- Increased intracranial pressure
Key clinical trials
- General Anesthesia and General Anesthesia Combined With Thoracic Epidural Anesthesia (NA)
- The Effect of Deep Versus Moderate Muscle Relaxants in Men During and After Robotic Surgery for Prostate Cancer (PHASE2)
- Application of Low-dose Muscle Relaxants in Bronchoscopic Interventional Procedures (NA)
- Comparison of the Effects of Total Intravenous Anaesthesia With Target-Controlled Infusion (TCI) and Inhalation Anaesthesia on Airway Complications During Extubation and in the Early Postoperative Period in Thyroidectomy Surgery (NA)
- Emergence Agitation (NA)
- Developing a Physiology-Pharmacodynamic Model of Rocuronium Dose and Cardiac Output to Investigate the Onset Time of Neuromuscular Relaxation (PHASE4)
- Remimazolam Infusion in Kidney Transplant Patients: A Multicenter Study (PHASE1)
- Comparison of The Effects Of General Anesthesia and PECS Block Methods on Blood Counts in Patients With Breast Cancer
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Muscle Relaxant (Rocuronium) CI brief — competitive landscape report
- Muscle Relaxant (Rocuronium) updates RSS · CI watch RSS
- Ostfold Hospital Trust portfolio CI